Weave (WEAV) Q2 2026 Earnings Call Transcript

Weave reported Q2 2026 total revenue of $67.5M (+15.5% YoY), with payments revenue growing at roughly 2x the rate of total revenue. Profitability improved materially: non-GAAP operating income rose to $3.2M (vs. ~$0.1M in Q2 2025) and the non-GAAP operating margin reached 4.7% (+460 bps YoY), while sales & marketing dropped 240 bps sequentially to 38% of revenue. The company raised FY2026 non-GAAP operating income guidance to $12M–$14M and updated FY revenue to $273M–$275M, but noted a May–July go-to-market transition created booking shortfalls that are expected to flow through in the back half; Q3 revenue guidance is $68.6M–$69.6M with operating income of $3M–$4M.

Analysis

The setup is less about near-term revenue and more about whether the company is resetting its cost of growth to a higher-quality trajectory. The margin expansion suggests the operating model can scale, but the market will only pay for that if bookings re-accelerate after the sales-org changes; otherwise this looks like a self-inflicted revenue air pocket. In the next 30-60 days, the stock is likely to trade on confidence in the new SDR/vertical model, not on AI engagement metrics.

The underappreciated winner is the embedded healthcare workflow stack around athenahealth and dental/DSO consolidation. Deeper integration should raise switching costs and improve LTV/CAC over 6-18 months, which is more important than any single quarter of add counts. That dynamic also pressures smaller point solutions and human-heavy front-office workflows: once scheduling, reminders, and payment collection are bundled into one system of action, discretionary spend should shift away from staffing and toward software attach.

Contrarian risk: the market may be over-discounting the guide cut as demand weakness when the disclosure points to execution timing. If August/September booking cadence normalizes, the current reset becomes a setup for multiple expansion because the business is showing real operating leverage and free-cash-flow inflection. The falsifier is simple: if Q3 bookings, NRR, or specialty-medical add trends fail to improve after the sales reorganization, this is not just timing, it is a durability problem.

Key Decisions for Investors

• Starter long WEAV on post-earnings weakness only if the stock gaps down on the reduced revenue guide; think 3-6 month horizon, with upside tied to evidence that September bookings re-accelerate and Q4 waterfalled revenue inflects.
• Do not chase the stock on the AI narrative alone. Treat AI interactions as a leading indicator for attach/retention, not earnings; wait for proof in ARPU, payments mix, or NRR before adding aggressively.
• Use a hard stop on the long if the next quarterly update shows no improvement in bookings or if management is forced to cut 2026 revenue again; that would confirm the GTM reset is more than timing.
• Watch specialty medical as the key operating lever: if athenahealth-linked deals start lifting ASP and retention over the next 1-2 quarters, add to WEAV because the valuation could re-rate on improved unit economics rather than headline growth.
• No immediate pair trade is attractive here; if you want exposure, prefer a selective long WEAV versus staying flat until the post-transition cadence is visible in monthly sales data.